Adverum Biotechnologies Inc (ADVM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Adverum Biotechnologies Inc (ADVM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH374087D
  • |
  • Pages: 54
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Adverum Biotechnologies Inc (Adverum), formerly Avalanche Biotechnologies Inc, is a clinical-stage gene therapy provider. The company's product pipeline includes AVDM-053, ADVM-022 and AVA-311. Its products are used for treatment of antitrypsin deficiency, hereditary angioedema, wet age-related macular degeneration and juvenile X-linked retinoschisis a retinal disease caused by mutations. The company provides its ocular biofactory gene therapy platform to develop product candidates for rare diseases in the field of ophthalmology. It has collaborations with academic institutions and pharmaceutical companies, among others. It also offers research and development, pre clinical services and manufacturing services. Adverum is headquartered in Menlo Park, California, the US.

Adverum Biotechnologies Inc (ADVM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Avalanche Biotech Raises USD 55 Million In Series B Venture Financing 12

Partnerships 14

Adverum Biotechnologies Extends Agreement with Editas Medicine 14

Synpromics Expanded its Research Agreement with Adverum Biotech 15

Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 16

Licensing Agreements 17

Avalanche Biotech Enters into Licensing Agreement with University of Washington 17

GenSight Biologics Enters into Licensing Agreement with Avalanche Biotech 18

Equity Offering 20

Adverum Biotech Raises USD69 Million in Public Offering of Shares 20

Adverum Biotech to Raise up to USD50 Million in Public Offering of Shares 22

Avalanche Biotechnologies Raises USD140 Million in Public Offering of Shares 23

Avalanche Biotech Completes IPO for USD117 Million 25

Avalanche Biotech Raises USD10 Million in Private Placement of Shares 27

Acquisition 28

Avalanche Biotech Acquires Annapurna Therapeutics 28

Adverum Biotechnologies Inc-Key Competitors 30

Adverum Biotechnologies Inc-Key Employees 31

Adverum Biotechnologies Inc-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Aug 08, 2018: Adverum Biotechnologies reports second quarter 2018 financial results and provides corporate update 33

May 09, 2018: Adverum Biotechnologies Reports First Quarter 2018 Financial Results and Provides Corporate Update 35

Mar 06, 2018: Adverum Biotechnologies Reports Fourth Quarter 2017 Financial Results and Provides Corporate Update 37

Nov 08, 2017: Adverum Biotechnologies Reports Third Quarter 2017 Financial Results and Provides Corporate Update 39

Aug 08, 2017: Adverum Biotechnologies Reports Second Quarter 2017 Financial Results and Provides Update 40

May 09, 2017: Adverum Biotechnologies Reports First Quarter 2017 Financial Results and Provides Update 41

Mar 06, 2017: Adverum Biotechnologies Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Update 42

Corporate Communications 44

Oct 17, 2018: Adverum Biotechnologies Announces Appointment of Leone Patterson as CEO and Member of the Board of Directors 44

May 03, 2018: Adverum Biotechnologies Announces Leadership Changes 45

Sep 07, 2017: Adverum Biotechnologies Appoints Eric G. Carter, M.D., Ph.D. to Board of Directors 46

Jun 20, 2017: Adverum Biotechnologies appoints senior vice president and chief medical officer 47

Apr 20, 2017: Adverum Biotechnologies Appoints Richard N. Spivey, Pharm.D., Ph.D. to Board of Directors 48

Mar 14, 2017: Adverum Biotechnologies Appoints Patrick Machado, J.D. to Board of Directors 49

Product News 50

Aug 01, 2018: Adverum Biotechnologies announces clinical progress across gene therapy Pipeline 50

Product Approvals 52

Jan 04, 2018: Adverum Biotechnologies Provides Update on its Hereditary Angioedema Drug Candidate ADVM-053 52

Other Significant Developments 53

Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54

List of Figures

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adverum Biotechnologies Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Avalanche Biotech Raises USD 55 Million In Series B Venture Financing 12

Adverum Biotechnologies Extends Agreement with Editas Medicine 14

Synpromics Expanded its Research Agreement with Adverum Biotech 15

Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 16

Avalanche Biotech Enters into Licensing Agreement with University of Washington 17

GenSight Biologics Enters into Licensing Agreement with Avalanche Biotech 18

Adverum Biotech Raises USD69 Million in Public Offering of Shares 20

Adverum Biotech to Raise up to USD50 Million in Public Offering of Shares 22

Avalanche Biotechnologies Raises USD140 Million in Public Offering of Shares 23

Avalanche Biotech Completes IPO for USD117 Million 25

Avalanche Biotech Raises USD10 Million in Private Placement of Shares 27

Avalanche Biotech Acquires Annapurna Therapeutics 28

Adverum Biotechnologies Inc, Key Competitors 30

Adverum Biotechnologies Inc, Key Employees 31

Adverum Biotechnologies Inc, Subsidiaries 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Adverum Biotechnologies Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17833
Site License
USD 500 INR 35665
Corporate User License
USD 750 INR 53498

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com